Abbott announced that the U.S. FDA has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system, which features the world’s smallest, thinnest and most discreet glucose sensor. With the FDA’s clearance of a standalone reader, Abbott is working to get the FreeStyle Libre 3 system added to Medicare’s list of covered systems as soon as possible.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Needham med tech analysts to hold an analyst/industry conference call
- Abbott says no FreeStyle Libre readers being physically recalled
- FDA Classifies Abbott’s (NYSE:ABT) Freestyle Libre Readers Recall as the Most Serious Type
- Abbott price target lowered to $115 from $125 at BofA
- Abbott assumed with a Buy at UBS